Edition:
United Kingdom

Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

83.47EUR
4:39pm BST
Change (% chg)

€0.60 (+0.72%)
Prev Close
€82.87
Open
€82.17
Day's High
€83.72
Day's Low
€82.14
Volume
1,944,737
Avg. Vol
2,527,660
52-wk High
€83.86
52-wk Low
€62.50

SASY.PA

Chart for SASY.PA

About

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company's segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including... (more)

Overall

Beta: 0.89
Market Cap(Mil.): €107,069.90
Shares Outstanding(Mil.): 1,292.02
Dividend: 2.96
Yield (%): 3.57

Financials

  SASY.PA Industry Sector
P/E (TTM): 24.46 29.18 29.98
EPS (TTM): 3.39 -- --
ROI: 5.02 13.62 13.13
ROE: 7.60 14.52 14.27

BRIEF-Vivus reacquires Stendra(R)(AVANAFIL)commercial rights from Sanofi

* Reacquires Stendra(R) (Avanafil) commercial rights from Sanofi

1:48pm BST

Crunch week looms for Sanofi, Roche and GSK at U.S. drugs agency

LONDON Three of Europe's top drugmakers face critical verdicts from U.S. regulators next week, with Sanofi and Roche likely to win approvals for two new products, while GlaxoSmithKline braces for a potential generic rival.

23 Mar 2017

Crunch week looms for Sanofi, Roche and GSK at U.S. drugs agency

LONDON Three of Europe's top drugmakers face critical verdicts from U.S. regulators next week, with Sanofi and Roche likely to win approvals for two new products, while GlaxoSmithKline braces for a potential generic rival.

23 Mar 2017

Crunch week looms for Sanofi, Roche and GSK at U.S. drugs agency

LONDON, March 23 Three of Europe's top drugmakers face critical verdicts from U.S. regulators next week, with Sanofi and Roche likely to win approvals for two new products, while GlaxoSmithKline braces for a potential generic rival.

23 Mar 2017

BRIEF-Sanofi genzyme extends its multiple myeloma journey partners program

* Sanofi genzyme extends its multiple myeloma journey partners program to cities nationwide to help improve patient outcomes through peer-to-peer education Source text for Eikon: Further company coverage:

22 Mar 2017

Sanofi, Regeneron sue Amgen to protect eczema drug from patent claims

BOSTON Sanofi SA and Regeneron Pharmaceuticals Inc have filed a lawsuit seeking a court order declaring that their eczema drug Dupixent, awaiting a U.S. approval decision, does not infringe an Amgen Inc patent for a failed asthma treatment.

21 Mar 2017

UPDATE 1-Sanofi, Regeneron sue Amgen to protect eczema drug from patent claims

BOSTON, March 21 Sanofi SA and Regeneron Pharmaceuticals Inc have filed a lawsuit seeking a court order declaring that their eczema drug Dupixent, awaiting a U.S. approval decision, does not infringe an Amgen Inc patent for a failed asthma treatment.

21 Mar 2017

Sanofi, Regeneron sue Amgen to protect eczema drug from patent claims

BOSTON, March 21 Sanofi SA and Regeneron Pharmaceuticals Inc filed a lawsuit seeking a court order declaring that their eczema drug Dupixent, awaiting a U.S. approval decision, does not infringe an Amgen Inc patent for a failed asthma treatment.

21 Mar 2017

UK gives early green light to Sanofi eczema drug

LONDON Sanofi has won an early green light from Britain for its game-changing eczema medicine, boosting the French company's hopes for a product that is also expected to win approval in the U.S. market this month.

14 Mar 2017

UK gives early green light to Sanofi eczema drug

LONDON, March 14 Sanofi has won an early green light from Britain for its game-changing eczema medicine, boosting the French company's hopes for a product that is also expected to win approval in the U.S. market this month.

14 Mar 2017

More From Around the Web

Earnings vs. Estimates